FindTrial
Sign In

Coronary Artery Stenting

DEVICE6 trials

Sponsors

Medtronic Vascular, Boston Scientific Corporation, Clinical Centre of Serbia, Tryton Medical, Inc.

Conditions

Coronary Artery DiseaseCoronary Heart DiseaseMyocardial Infarction

Phase 1

The Medtronic RESOLUTE Clinical Trial
CompletedNCT00248079
Medtronic VascularCoronary Artery Disease
Start: 2005-11-30End: 2011-10-31Updated: 2011-10-20

Unknown Phase

The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions
CompletedNCT00217269
Medtronic VascularCoronary Artery Disease
Start: 2005-04-30End: 2011-07-31Updated: 2012-04-20
The ENDEAVOR Pharmacokinetic (PK) Registry: The Medtronic Endeavor Drug Eluting Coronary Stent System
CompletedNCT00314275
Medtronic VascularCoronary Artery Disease
Start: 2006-01-31End: 2011-08-31Updated: 2012-04-20
TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)
CompletedNCT01242696
Boston Scientific CorporationCoronary Heart Disease
Start: 2010-11-30End: 2015-07-31Updated: 2017-02-03
Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients
CompletedNCT02419833
Clinical Centre of SerbiaMyocardial Infarction
Start: 2009-09-30End: 2018-03-31Updated: 2020-07-13
Tryton Post Approval Study (PAS) for the Tryton Side Branch Stent
NCT03318796
Tryton Medical, Inc.Coronary Artery Disease
Start: 2018-01-22End: 2022-12-30Target: 335Updated: 2019-02-26

Related Papers

Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients: The RIDDLE-NSTEMI Study.
2016-01-06107 citations
One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE)
EuroIntervention2015-03-015 citations
Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
2013-03-2075 citations
The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
2013-03-2047 citations
Impact of polymer formulations on neointimal proliferation after zotarolimus-eluting stent with different polymers: insights from the RESOLUTE trial.
2011-05-1716 citations
Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
2010-10-0162 citations
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
2010-02-01162 citations
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
2009-12-0138 citations
Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.
2009-10-0187 citations
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
2009-08-0133 citations